[1] RIDLEY A J. Rho GTPase signalling in cell migration[J]. Curr Opin Cell Biol, 2015, 36:103-112.
[2] XIAO X H, LV L C, DUAN J, et al. Regulating Cdc42 and its signaling pathways in cancer:small molecules and MicroRNA as new treatment candidates[J]. Molecules, 2018, 23(4):E787.
[3] JOHNSON J L, ERICKSON J W, CERIONE R A. C-terminal di-arginine motif of Cdc42 protein is essential for binding to phosphatidylinositol 4, 5-bisphosphate-containing membranes and inducing cellular transformation[J]. J Biol Chem, 2012, 287(8):5764-5774.
[4] BRODEUR G M, SEEGER R C, SCHWAB M, et al. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage[J]. Science, 1984, 224(4653):1121-1124.
[5] LEE S, CRAIG B T, ROMAIN C V, et al. Silencing of CDC42 inhibits neuroblastoma cell proliferation and transformation[J]. Cancer Lett, 2014, 355(2):210-216.
[6] LIBERMANN T A, NUSBAUM H R, RAZON N, et al. Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin[J]. Nature, 1985, 313(5998):144-147.
[7] WU W J, TU S N, CERIONE R A. Activated Cdc42 sequesters c-Cbl and prevents EGF receptor degradation[J]. Cell, 2003, 114(6):715-725.
[8] BUCHWALD M, PIETSCHMANN K, BRAND P, et al. SIAH ubiquitin ligases target the nonreceptor tyrosine kinase ACK1 for ubiquitinylation and proteasomal degradation[J]. Oncogene, 2013, 32(41):4913-4920.
[9] ZHANG Y, LI J, LAI X N, et al. Focus on Cdc42 in breast cancer:new insights, target therapy development and non-coding RNAs[J]. Cells, 2019, 8(2):E146.
[10] XU Y R, QI Y Z, LUO J, et al. Hepatitis B virus X protein stimulates proliferation, wound closure and inhibits apoptosis of HuH-7 cells via CDC42[J]. Int J Mol Sci, 2017, 18(3):E586.
[11] PAUL C D, MISTRIOTIS P, KONSTANTOPOULOS K. Cancer cell motility:lessons from migration in confined spaces[J]. Nat Rev Cancer, 2017, 17(2):131-140.
[12] YAMAO M, NAOKI H, KUNIDA K, et al. Distinct predictive performance of Rac1 and Cdc42 in cell migration[J]. Sci Rep, 2015, 5:17527.
[13] RADU M, SEMENOVA G, KOSOFF R, et al. PAK signalling during the development and progression of cancer[J]. Nat Rev Cancer, 2014, 14(1):13-25.
[14] RANE C K, MINDEN A. P21 activated kinase signaling in cancer[J]. Semin Cancer Biol, 2019, 54:40-49.
[15] SIPES N S, FENG Y X, GUO F K, et al. Cdc42 regulates extracellular matrix remodeling in three dimensions[J]. J Biol Chem, 2011, 286(42):36469-36477.
[16] KESANAKURTI D, CHETTY C, RAJASEKHAR MADDIRELA D, et al. Functional cooperativity by direct interaction between PAK4 and MMP-2 in the regulation of anoikis resistance, migration and invasion in glioma[J]. Cell Death Dis, 2012, 3:e445.
[17] QADIR M I, PARVEEN A, ALI M. Cdc42:role in cancer management[J]. Chem Biol Drug Des, 2015, 86(4):432-439.
[18] SWAINE T, DITTMAR M T. CDC42 use in viral cell entry processes by RNA viruses[J]. Viruses, 2015, 7(12):6526-6536.
[19] YANG J Q, KALIM K W, LI Y, et al. Rational targeting Cdc42 restrains Th2 cell differentiation and prevents allergic airway inflammation[J]. Clin Exp Allergy, 2019, 49(1):92-107. |
